What is HC Wainwright’s Forecast for VTVT Q1 Earnings?

vTv Therapeutics Inc. (NASDAQ:VTVT) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of vTv Therapeutics in a note issued to investors on Wednesday, April 9th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will earn ($0.73) per share for the quarter. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.94) EPS, FY2028 earnings at ($3.67) EPS and FY2029 earnings at ($2.70) EPS.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.32. The business had revenue of $0.02 million for the quarter.

Separately, StockNews.com initiated coverage on shares of vTv Therapeutics in a research note on Thursday, March 27th. They issued a “sell” rating for the company.

vTv Therapeutics Trading Up 17.3 %

NASDAQ VTVT opened at $18.53 on Thursday. The firm has a market capitalization of $59.11 million, a price-to-earnings ratio of -4.09 and a beta of 0.81. The firm’s 50 day simple moving average is $17.83 and its 200 day simple moving average is $15.69. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $29.19.

Hedge Funds Weigh In On vTv Therapeutics

Several large investors have recently modified their holdings of VTVT. FMR LLC bought a new position in vTv Therapeutics during the third quarter worth $2,402,000. JPMorgan Chase & Co. acquired a new stake in vTv Therapeutics in the fourth quarter worth $25,000. Finally, Geode Capital Management LLC grew its holdings in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the last quarter. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.